Matthew Mullen
Rheumatology · Birmingham, ALNPI 1336439595
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 87.0% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $33,343, more than ten times the $17 reported in 2022.
Across 223 payments — averaging $169.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$33K
- AbbVie$2K
- Novartis$607
- Amgen$508
- Sanofi$466
- GSK$366
- plus $1K from 12 others
What the payments were for
- Consulting fees$4,86413%
- Speaking & faculty fees$21,23356%
- Travel & lodging$5,67615%
- Food & beverage$6,05116%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 53 | $32,920 |
| AbbVie | 41 | $1,567 |
| Novartis | 18 | $607 |
| Amgen | 22 | $508 |
| Sanofi | 9 | $466 |
| GSK | 16 | $366 |
| UCB, Inc. | 20 | $339 |
| AstraZeneca | 6 | $309 |
| Pfizer | 15 | $232 |
| Mallinckrodt Hospital Products Inc. | 7 | $182 |
| Lilly USA, LLC | 4 | $96 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Organon | 3 | $50 |
| Sobi, Inc | 1 | $31 |
| Almatica Pharma LLC | 1 | $25 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Sandoz | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,824 in reported general payments places this provider in the 85th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 130 | $982,986 |
| Enbrel SureclickEtanercept | 104 | $774,181 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 80 | $736,881 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 19 | $297,670 |
| Taltz AutoinjectorIxekizumab | 28 | $274,245 |
| Orencia ClickjectAbatacept | 45 | $243,517 |
| TremfyaGuselkumab | 17 | $222,630 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $222,347 |
| BenlystaBelimumab | 45 | $208,871 |
| Humira PenAdalimumab | 24 | $175,367 |
| Xeljanz XrTofacitinib Citrate | 22 | $144,454 |
| RinvoqUpadacitinib | 20 | $127,415 |
| KineretAnakinra | 14 | $121,927 |
| ActemraTocilizumab | 33 | $116,971 |
| Cosentyx Sensoready PenSecukinumab | 16 | $111,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya, Remicade | $32,920 | $273,82432 claims |
| GSKBenlysta | $366 | $208,87145 claims |
| AmgenEnbrel, Avsola | $508 | $148,69932 claims |
| AbbVieRinvoq, Restasis | $1,567 | $133,81431 claims |
| SanofiKevzara | $466 | $84,39520 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $17 | $70,30312 claims |
| PfizerXeljanz | $232 | $59,30712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Birmingham
- Jeffrey CurtisBirmingham$612K
- David McLainBirmingham$588K
- Kenneth SaagBirmingham$143K
- Maria DanilaBirmingham$46K
- Angelo Gaffo LlontopBirmingham$36K
- Greg EudyBirmingham$33K
- John MorganBirmingham$11K
- Jose Rubio MosqueraBirmingham$8K
- Kurt BlakeBirmingham$7K
- Amanda AlexanderBirmingham$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.